FDA Grants Priority Review to Zepzelca Combo for Small Cell Lung Cancer

GO2 for Lung Cancer and ALCMI Launch SUCCEED, a Groundbreaking Remote Clinical Study Targeting Small Cell Lung Cancer - GO2 for Lung Cancer

Innovative decentralized trial aims to increase patient participation and accelerate research for one of the deadliest, under-researched lung cancers  SAN CARLOS, CA – June 12, 2025 — GO2 for Lung Cancer (GO2) and the Addario Lung Cancer Medical Institute (ALCMI) have launched SUCCEED, a landmark, remote-participation, observational clinical study in small cell lung cancer (SCLC), one of the deadliest and most under-researched cancers.  Despite …

FDA Grants Priority Review to Zepzelca Combo for Small Cell Lung Cancer

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.